Home > Boards > US Listed > Biotechs > Imugene, Ltd. (IUGNF)

CF33 Oncolytic Virus GMP Manufacturing Update

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Bottom Fisher Member Profile
Followed By 27
Posts 1,052
Boards Moderated 0
Alias Born 07/02/19
160x600 placeholder
Bottom Fisher   Tuesday, 11/26/19 09:30:47 AM
Re: None
Post # of 58 
CF33 Oncolytic Virus GMP Manufacturing Update

SYDNEY Australia 25 November 2019: Imugene Limited (ASX: IMU) is pleased to provide a GMP
manufacturing update for its CF33 oncolytic virus technology, which is due to enter clinical trials in
The CF33 oncolytic virus (OV) was developed in the lab of Professor Yuman Fong, an internationally
recognised surgeon and scientist at City of Hope, a world-renowned independent research and
treatment centre for cancer, diabetes and other life-threatening diseases based in California.
As previously announced, CF33 has been developed in two different constructs: one version of the
OV is “armed” with an immune checkpoint inhibitor inserted in the virus, which is known as
CheckVacc; and the other an unarmed construct, known as Vaxinia. It is planned by Imugene that
two separate Phase 1 clinical trials will be conducted in 2020 to test a CheckVacc construct and a
Vaxinia construct of the OV.
Both constructs have completed clinical grade GMP batches at the City of Hope Center for
Biomedicine and Genetics (CBG).
The CBG is a California-licensed, 20,000 square foot, multi-product biologics manufacturing facility
within City of Hope. With twelve ISO 7 production rooms in three product type “zones”, a dedicated
aseptic fill suite and a staff with extensive biopharmaceutical experience, the CBG is capable of
producing virtually any type of biologic at scales suitable for Phase I through Phase II clinical
Imugene’s M.D. & CEO, Ms Leslie Chong said, “This is a significant milestone met in our
preparation for commencing our planned CF33 oncolytic virus Phase 1 clinical trials in 2020”.
For further information please contact:
Leslie Chong
Managing Director and Chief Executive Officer
T: +61 458 040 433
E: Leslie.Chong@Imugene.com
Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences